Prefer Wyeth, says Sudarshan Sukhani

Sudarshan Sukhani of s2analytics.com told CNBC-TV18, "Momentum should continue in both Wyeth and Pfizer. They have broken out of very long basis, they are always darlings of the market, so both should see higher levels. It is very difficult to chose between the two but even then Wyeth probably is a better option if one wants to make further investments."

At 11:47 hrs Wyeth was quoting at Rs 932, up Rs 117.85, or 14.48 percent. It has touched an intraday high of Rs 976.95 and an intraday low of Rs 875. The share touched its 52-week high Rs 989 and 52-week low Rs 553.05 on 30 November, 2012 and 06 September, 2013, respectively.Currently, it is trading 5.76 percent below its 52-week high and 68.52 percent above its 52-week low.Market capitalisation stands at Rs 2,117.51 crore.